Immune privilege

Certain sites of the mammalian body have immune privilege, meaning they are able to tolerate the introduction of antigens without eliciting an inflammatory immune response. Tissue grafts are normally recognised as foreign antigen by the body and attacked by the immune system. However, in immune privileged sites, tissue grafts can survive for extended periods of time without rejection occurring.[1] Immunologically privileged sites include:

Immune privilege is also believed to occur to some extent or able to be induced in articular cartilage.[2][3][4] This was once thought to also include the brain, but this is now known to be incorrect, as it has been shown that immune cells of the central nervous system contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood.[5]

Immune privilege is thought to be an evolutionary adaptation to protect vital structures from the potentially damaging effects of an inflammatory immune response. Inflammation in the brain or eye can lead to loss of organ function, while immune responses directed against a fetus can lead to miscarriage.

Medically, a cornea transplant[6] takes advantage of this, as does knee meniscal transplantation.[7]

Mechanisms

Antigens from immune privileged regions have been found to interact with T cells in an unusual way: inducing tolerance of normally rejected stimuli.[8] Immune privilege has emerged as an active rather than a passive process.

Physical structures surrounding privileged sites cause a lack of lymphatic drainage, limiting the immune system's ability to enter the site. Other factors that contribute to the maintenance of immune privilege include:

  • low expression of classical MHC class Ia molecules
  • expression of immunoregulatory nonclassical, low polymorphic class Ib MHC molecules
  • increased expression of surface molecules that inhibit complement activation
  • local production of immunosuppressive cytokines such as TGF-β[9]
  • presence of neuropeptides
  • constitutive expression of Fas ligand that controls the entry of Fas-expressing lymphoid cells.[1][10]

The nature of isolation of immunologically privileged sites from the rest of the body's immune system can cause them to become targets of autoimmune diseases or conditions, including sympathetic ophthalmia in the eye.

Immunologically privileged sites

Eye
Main article: Ocular immune system

As well as the mechanisms that limit immune cell entry and induce immune suppression, the eye contains active immune cells that act upon the detection of foreign antigens. These cells interact with the immune system to induce unusual suppression of the systemic immune system response to an antigen introduced into the eye. This is known as Anterior Chamber Associated Immune Deviation (ACAID).[11][12]

Sympathetic ophthalmia is a rare disease which results from the isolation of the eye from the systemic immune system. Usually, trauma to one eye induces the release of eye antigens which are recognized and picked up by local antigen presenting cells (APC) such as macrophages and dendritic cells. These APC carry the antigen to local lymph nodes to be sampled by T cells and B cells. Entering the systemic immune system, these antigens are recognized as foreign and an immune response is mounted against them. The result is the sensitization of immune cells against a self-protein, causing an autoimmune attack on both the damaged eye and the non-damaged eye.[8]

In this manner, the immune-privileged property has served to work against the eye instead. T cells normally encounter self-antigens during their development, when they move to the tissue draining lymph nodes. Anergy is induced in T cells which bind to self-antigens, deactivating them and preventing an autoimmune response in the future. However, the physical isolation of eye antigens results in the body's T cells never having encountered them at any time during development. Studies in mice have shown that the lack of presentation of eye self-antigens to specific T cells will fail to induce a sufficient amount of anergy to the self-antigens. While the lack of antigen presentation (due to the physical barriers) is sufficient to prevent the activation of autoreactive immune cells to the eye, the failure to induce sufficient anergy to T cells has detrimental results. In the case of damage or chance presentation to the immune system, the antigen presentation and immune response will occur at elevated rates.[13]

Placenta and fetus
Main article: Immune tolerance in pregnancy

The mother's immune system is able to provide protection from microbial infections without mounting an immune response against fetal tissues expressing paternally inherited alloantigens. A better understanding of the immunology of pregnancy may lead to the discovery of reasons for miscarriage.

Regulatory T cells (Tregs) appear to be important in the maintenance of tolerance to fetal antigen. Increased numbers of Tregs are found during normal pregnancy. In both mouse models and humans diminished numbers of Tregs were associated with immunological rejection of the fetus and miscarriage. Experiments in mice involving the transfer of CD4+/CD25+ Treg cells from normal pregnant mice into abortion-prone animals resulted in the prevention of abortion.[14] This confirmed the importance of these cells in maintaining immune privilege in the womb.

A number of theories exist as to the exact mechanism by which fetal tolerance is maintained. It has been proposed in recent literature[15] that a tolerant microenvironment is created at the interface between the mother and fetus by regulatory T-cells producing "tolerant molecules". These molecules including heme oxygenase 1 (HO-1), leukaemia inhibitory factor (LIF), transforming growth factor β (TGF-β) and interleukin 10 (IL-10) have all been implicated in the induction of immune tolerance. Foxp3 and neuropillin are markers expressed by the regulatory T-cells by which they are identified.

Testes
Main article: Testicular immunology

Sperm are immunogenic – that is they will cause an autoimmune reaction if transplanted from the testis into a different part of the body. This has been demonstrated in experiments using rats by Lansteiner (1899) and Metchinikoff (1900),[16][17] mice[18] and guinea pigs.[19] The likely reason for their immunogenicity or rather antigenicity is that sperm first mature at puberty, after central tolerance has been established, therefore the body recognizes them as foreign and mounts an immune reaction against them.[20] Therefore, mechanisms for their protection must exist in this organ to prevent any autoimmune reaction. The blood–testis barrier is likely to contribute to the survival of sperm. However, it is believed in the field of testicular immunology that the blood–testis barrier cannot account for all immune suppression in the testis, due to (1) its incompleteness at a region called the rete testis[17] and (2) the presence of immunogenic molecules outside the blood–testis barrier, on the surface of spermatogonia.[16][17] The Sertoli cells play a crucial role in the protection of sperm from the immune system. They create the Sertoli cell barrier, which complements the blood-testis barrier.[21] The protection is ensured by tight junctions, which appear between two neighboring Sertoli cells.[22] Another mechanism which is likely to protect sperm is the suppression of immune responses in the testis.[23][24]

Central nervous system
Main article: Neuroimmune system

The central nervous system (CNS), which includes the brain and spinal cord, is a sensitive system with limited capacity for regeneration. In that regard, the concept of "immune privilege" within the CNS was once thought to be critical in limiting inflammation. The blood–brain barrier plays an important role in maintaining the separation of CNS from the systemic immune system but the presence of the blood–brain barrier, does not, on its own, provide immune privilege.[25] It is thought that immune privilege within the CNS varies throughout the different compartments of the system, being most pronounced in the parenchyma tissue or "white matter".[25]

The concept of CNS as an "immune-privileged" organ system, however, has been overwhelmingly challenged and re-evaluated over the last two decades. Current data not only indicate the presence of resident CNS macrophages (known as microglia) within the CNS, but there is also a wide body of evidence suggesting the active interaction of the CNS with peripheral immune cells.[26]

Generally, in normal (uninjured) tissue, antigens are taken up by antigen presenting cells (dendritic cells), and subsequently transported to the lymph nodes. Alternatively, soluble antigens can drain into the lymph nodes. In contrast, in the CNS, dendritic cells are not thought to be present in normal parenchymal tissue or perivascular space although they are present in the meninges and choroids plexus.[25] Thus, the CNS is thought to be limited in its capacity to deliver antigens to local lymph nodes and cause T-cell activation.[27]

Although there is no conventional lymphatic system in the CNS, the drainage of antigens from CNS tissue into the cervical lymph nodes has been demonstrated. The response elicited in the lymph nodes to CNS antigens is skewed towards B-cells. Dendritic cells from cerebrospinal fluid have been found to migrate to B-cell follicles of cervical lymph nodes.[28] The skewing of the response to antigen from the CNS towards a humoral response means that a more dangerous inflammatory T-cell response can be avoided.

The induction of systemic tolerance to an antigen introduced into the CNS has been previously shown.[29] This was seen in the absence of the T-cell mediated inflammatory "delayed type hypersensitivity reaction" (DTH) when the antigen was reintroduced in another part of the body. This response is analogous to ACAID in the eye.

Clinical applications

There is great potential for use of molecular mechanisms present in immune privileged sites in transplantations, especially allotransplantations. Compared to skin allografts, which are rejected in almost 100% of cases, corneal allografts survive long-term in 50-90% of cases. Immune privileged allografts survive even without immunosuppression, which is routinely applied to different tissue/organ recipients.[30] Research suggests that the exploitation of anterior chamber-associated immune deviation (ACAID), aqueous humor and its anti-inflammatory properties and the induction of regulatory T cells (Treg) may lead to increased survival of allotransplants.[31]

Another option of exploitation of immune privilege is gene therapy. Sertoli cells have already been used in research to produce insulin in live diabetic mice. The Sertoli cells were genetically engineered using recombinant lentivirus to produce insulin and then transplanted into mice. Even though the results were only short-term, the research team established that it is possible to use genetically engineered Sertoli cells in cell-therapy[32]

Sertoli cells were also exploited in experiments for their immunosuppressive function. They were used to protect and nurture islets producing insulin to treat type I diabetes. The exploitation of Sertoli cells significantly increased the survival of transplanted islets. However, more experiments must be conducted before this method may be tested in human medicine as part of clinical trials.[33] In another study on type II diabetic and obese mice, the transplantation of microencapsulated Sertoli cells in the subcutaneous abdominal fat depot lead to the return of normal glucose levels in 60% of the animals.[34]

History of research

The existence of immune privileged regions of the eye was recognized as early as the late 19th century and investigated by Peter Medawar.[35] The original explanation of this phenomenon was that physical barriers around the immune privileged site enabled it to avoid detection from the immune system altogether, preventing the immune system from responding to any antigens present. More recent investigations have revealed a number of different mechanisms by which immune privileged sites interact with the immune system.

References
  1. Hong S, Van Kaer L (November 1999). "Immune privilege: keeping an eye on natural killer T cells". The Journal of Experimental Medicine. 190 (9): 1197–200. doi:10.1084/jem.190.9.1197. PMC 2195673. PMID 10544192.
  2. Sun Z, Zhang M, Zhao XH, Liu ZH, Gao Y, Samartzis D, Wang HQ, Luo ZJ (2013). "Immune cascades in human intervertebral disc: the pros and cons". International Journal of Clinical and Experimental Medicine. 6 (6): 1009–1014. PMC 3657352. PMID 23696917.
  3. Fujihara Y, Takato T, Hoshi K (2014). "Macrophage-inducing FasL on chondrocytes forms immune privilege in cartilage tissue engineering, enhancing in vivo regeneration". Stem Cells. 32 (2): 1208–1219. doi:10.1002/stem.1636. PMID 24446149.
  4. Abazari A, Jomha NM, Elliott JA, McGann LE (2013). "Cryopreservation of articular cartilage". Cryobiology. 66 (3): 201–209. doi:10.1016/j.cryobiol.2013.03.001. PMID 23499618.
  5. Ziv, Y.et al (2006). Nature Neuroscience, Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood 9, 268 - 275.
  6. Niederkorn, Jerry Y. (2017-01-27). "Corneal Transplantation and Immune Privilege". International Reviews of Immunology. 32 (1): 57–67. doi:10.3109/08830185.2012.737877. ISSN 0883-0185. PMC 3885418. PMID 23360158.
  7. Garrett JC, Steensen RN, Stevensen RN (1991). "Meniscal transplantation in the human knee: a preliminary report". Arthroscopy: The Journal of Arthroscopic and Related Surgery. 7 (1): 57–62. doi:10.1016/0749-8063(91)90079-D. PMID 2009121.
  8. Janeway, C. A.Jr., Travers, P., Walport, M., Shlomchik. M.J. (2005). ImmunoBiology, the immune system in health and disease 6th Edition. Garland Science.
  9. "Autoimmunity". webMIC 419: Immunology. University of Arizona. Archived from the original on 2003-06-10.
  10. Green DR, Ware CF (June 1997). "Fas-ligand: privilege and peril". Proc Natl Acad Sci USA. 94 (12): 5986–90. Bibcode:1997PNAS...94.5986G. doi:10.1073/pnas.94.12.5986. PMC 33671. PMID 9177153.
  11. Keino H, Takeuchi M, Kezuka T, Hattori T, Usui M, Taguchi O, Streilein JW, Stein-Streilein J (March 2006). "Induction of eye-derived tolerance does not depend on naturally occurring CD4+CD25+ T regulatory cells". Investigative Ophthalmology & Visual Science. 47 (3): 1047–55. doi:10.1167/iovs.05-0110. PMID 16505040.
  12. Streilein JW, Stein-Streilein J (2002). "Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy". International Reviews of Immunology. 21 (2–3): 123–52. doi:10.1080/08830180212066. PMID 12424840. S2CID 40690072.
  13. Lambe T, Leung JC, Ferry H, Bouriez-Jones T, Makinen K, Crockford TL, Jiang HR, Nickerson JM, Peltonen L, Forrester JV, Cornall RJ (2007). "Limited Peripheral T Cell Anergy Predisposes to Retinal Autoimmunity". The Journal of Immunology. 178 (7): 4276–4283. doi:10.4049/jimmunol.178.7.4276. PMID 17371984.
  14. Zenclussen A.C. (2006). "Regulatory T cells in pregnancy". Springer Seminars in Immunopathology. 28 (1): 31–39. doi:10.1007/s00281-006-0023-6. PMID 16838178. S2CID 40735131.
  15. Zenclussen AC, Schumacher A, Zenclussen ML, Wafula P, Volk HD (April 2007). "Immunology of pregnancy: cellular mechanisms allowing fetal survival within the maternal uterus". Expert Reviews in Molecular Medicine. 9 (10): 1–14. doi:10.1017/S1462399407000294. PMID 17462112. S2CID 12507493.
  16. Hedger MP, Hales DB (2006). "Immunophysiology of the Male Reproductive Tract". In Neill JD (ed.). Knobil and Neill's Physiology of Reproduction. Elsevier. pp. 1195–1286. ISBN 978-0-12-515401-7.
  17. Fijak M, Meinhardt A (2006). "The testis in immune privilege". Immunological Reviews. 213 (1): 66–81. doi:10.1111/j.1600-065X.2006.00438.x. PMID 16972897. S2CID 3048709.
  18. Kohno S, Munoz JA, Williams TM, Teuscher C, Bernard CC, Tung KS (1983). "Immunopathology of murine experimental allergic orchitis". J. Immunol. 130 (6): 2675–2682. PMID 6682874.
  19. Teuscher C, Wild GC, Tung KS (1982). "Immunochemical analysis of guinea pig sperm autoantigens". Biol. Reprod. 26 (2): 218–229. doi:10.1095/biolreprod26.2.218. PMID 7039703.
  20. Kaur, Gurvinder; Thompson, Lea Ann; Dufour, Jannette M. (2014-06-01). "Sertoli cells – Immunological sentinels of spermatogenesis". Seminars in Cell & Developmental Biology. Regulation of Spermatogenesis Part II & DNA Replication. 30: 36–44. doi:10.1016/j.semcdb.2014.02.011. PMC 4043859. PMID 24603046.
  21. Kaur, Gurvinder; Thompson, Lea Ann; Dufour, Jannette M. (2017-01-27). "Sertoli cells- Immunological sentinels of spermatogenesis". Seminars in Cell & Developmental Biology. 30: 36–44. doi:10.1016/j.semcdb.2014.02.011. ISSN 1084-9521. PMC 4043859. PMID 24603046.
  22. Mital, Payal; Hinton, Barry T.; Dufour, Jannette M. (2011-05-01). "The blood-testis and blood-epididymis barriers are more than just their tight junctions". Biology of Reproduction. 84 (5): 851–858. doi:10.1095/biolreprod.110.087452. ISSN 1529-7268. PMC 4574632. PMID 21209417.
  23. Kern S, Robertson SA, Mau VJ, Maddocks S (1995). "Cytokine secretion by macrophages in the rat testis". Biol. Reprod. 53 (6): 1407–1416. doi:10.1095/biolreprod53.6.1407. PMID 8562698.
  24. O'Bryan MK, Gerdprasert O, Nikolic-Paterson DJ, Meinhardt A, Muir JA, Foulds LM, Phillips DJ, de Kretser DM, Hedger MP (2005). "Cytokine profiles in the testes of rats treated with lipopolysaccharide reveal localized suppression of inflammatory responses". Am J Physiol Regul Integr Comp Physiol. 288 (6): R1744–R1755. doi:10.1152/ajpregu.00651.2004. PMID 15661966. S2CID 15841104.
  25. Galea I, Bechmann I, Perry VH (January 2007). "What is immune privilege (not)?". Trends in Immunology. 28 (1): 12–8. doi:10.1016/j.it.2006.11.004. PMID 17129764.
  26. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC (October 2006). "CNS immune privilege: hiding in plain sight". Immunol. Rev. 213 (1): 48–65. doi:10.1111/j.1600-065X.2006.00441.x. PMC 2633103. PMID 16972896.
  27. Mendez-Fernandez Y.V.; et al. (2005). "Anatomical and cellular requirements for the activation and migration of virus-specific CD8+ T cells to the brain during Theiler's virus infection". Journal of Virology. 79 (5): 3063–3070. doi:10.1128/jvi.79.5.3063-3070.2005. PMC 548433. PMID 15709026.
  28. Hatterer E, et al. (2006). "How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes". Blood. 107 (2): 806–812. doi:10.1182/blood-2005-01-0154. PMID 16204309.
  29. Wenkel H, et al. (2000). "Systemic immune deviation in the CNS does not necessarily depend on the integrity of the blood–brain barrier". Journal of Immunology. 164 (10): 5125–5131. doi:10.4049/jimmunol.164.10.5125. PMID 10799870.
  30. Niederkorn, Jerry Y. (2013-01-13). "Corneal Transplantation and Immune Privilege". International Reviews of Immunology. 32 (1): 57–67. doi:10.3109/08830185.2012.737877. ISSN 0883-0185. PMC 3885418. PMID 23360158.
  31. Taylor, Andrew W. (2016-01-01). "Ocular Immune Privilege and Transplantation". Frontiers in Immunology. 7: 37. doi:10.3389/fimmu.2016.00037. PMC 4744940. PMID 26904026.
  32. Kaur, Gurvinder; Thompson, Lea Ann; Pasham, Mithun; Tessanne, Kim; Long, Charles R.; Dufour, Jannette M. (2017-01-04). "Sustained Expression of Insulin by a Genetically Engineered Sertoli Cell Line after Allotransplantation in Diabetic BALB/c Mice". Biology of Reproduction. 90 (5): 109. doi:10.1095/biolreprod.113.115600. ISSN 0006-3363. PMC 4076370. PMID 24695630.
  33. Li, Yang; Xue, Wujun; Liu, Hongbao; Fan, Ping; Wang, Xiaohong; Ding, Xiaoming; Tian, Xiaohui; Feng, Xinshun; Pan, Xiaoming (2013-02-20). "Combined Strategy of Endothelial Cells Coating, Sertoli Cells Coculture and Infusion Improves Vascularization and Rejection Protection of Islet Graft". PLOS ONE. 8 (2): e56696. Bibcode:2013PLoSO...856696L. doi:10.1371/journal.pone.0056696. ISSN 1932-6203. PMC 3577699. PMID 23437215.
  34. Luca, Giovanni; Arato, Iva; Mancuso, Francesca; Calvitti, Mario; Falabella, Giulia; Murdolo, Giuseppe; Basta, Giuseppe; Cameron, Don F.; Hansen, Barbara C. (2016-11-01). "Xenograft of microencapsulated Sertoli cells restores glucose homeostasis in db/db mice with spontaneous diabetes mellitus". Xenotransplantation. 23 (6): 429–439. doi:10.1111/xen.12274. ISSN 1399-3089. PMID 27678013. S2CID 46744082.
  35. Medawar, P. B. (2017-01-04). "Immunity to Homologous Grafted Skin. III. The Fate of Skin Homographs Transplanted to the Brain, to Subcutaneous Tissue, and to the Anterior Chamber of the Eye". British Journal of Experimental Pathology. 29 (1): 58–69. ISSN 0007-1021. PMC 2073079. PMID 18865105.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.